Advertisement

Topics

Crizotinib: New Standard for ALK+ Myofibroblastic Tumor

07:44 EDT 16 Apr 2018 | Medscape

With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor -- a very rare type of soft tissue sarcoma -- crizotinib should be the standard of care, say experts.
Medscape Medical News

Original Article: Crizotinib: New Standard for ALK+ Myofibroblastic Tumor

NEXT ARTICLE

More From BioPortfolio on "Crizotinib: New Standard for ALK+ Myofibroblastic Tumor"

Advertisement
Quick Search
Advertisement
Advertisement